0
Reviews
Potential roles for pharmacists in pharmacogenetics
Shareen Y. El-Ibiary, PharmD, BCPS; Christine Cheng, PharmD; Brian Alldredge, PharmD
J Am Pharm Assoc (2003) 2008;48:e21-e32. doi:10.1331/JAPhA.2008.07050

Abstract

Objectives  To highlight areas of pharmacogenetics in which pharmacists may play a role and to describe those roles in the context of specific examples from a major academic medical center.

Data sources  Literature search (PubMed) and personal interviews for the University of California at San Francisco case examples.

Data synthesis  The field of pharmacogenetics presents a wide range of opportunities for pharmacists. Specific roles for pharmacists are likely to fall within three major domains: developing research methodologies and setting research directions, establishing the value of pharmacogenetic testing in clinical practice, and participating in education and infrastructure development that moves pharmacogenetic technologies toward implementation.

Conclusion  As drug therapy experts, pharmacists are in a unique position to push the frontiers of pharmacogenetics in both the research and clinical practice environments.

Sign In
APhA Members 
Welcome to JAPhA.org! Please log in below using your APhA username and password. Update your APhA profile.
Not a Subscriber
New to JAPhA? Become an APhA member to receive a full subscription to both the print and online editions.

OR

Register for a FREE limited account to benefit from personalization features such as alerts.

References

Ito RK, Demers LM.  Pharmacogenomics and pharmacogenetics: Future role of molecular diagnostics in the clinical diagnostic laboratory.  Clin Chem.  2004;50:1526–7.[PubMed][CrossRef]
 
Brock TP, Valgus JM, Smith SR, Summers KM.  Pharmacogenomics: Implications and considerations for pharmacists.  Pharmacogenomics.  2003;4:321–30.[PubMed]
 
Johnson JA, Bootman JL, Evans WE, et al. Pharmacogenomics: A scientific revolution in pharmaceutical sciences and pharmacy practice: Report of the 2001-2002 Academic Affairs Committee Accessed at www.ajpe.org/legacy/pdfs/aj6604S03.pdf, January 3,  2007.
 
Clemerson JP, Payne K, Bissell P, Anderson C. Pharmacogenetics, the next challenge for pharmacy? Pharm World Sci.  2006;28:126–30.[PubMed]
 
Carrico JM.  Human Genome Project and pharmacogenomics: Implications for pharmacy.  J Am Pharm Assoc.  2000;40:115–6.
 
 How genetics could change pharmacy The Pharmaceutical Journal. 2003;270:508–9.
 
Zagaria M. The promise of pharmacogenomics: Optimizing drug therapy while limiting toxicity Accessed at www.uspharmacist.com/index.asp?show=article&page=8_1190.htm, January 14,  2008.
 
Vizirianakis IS.  Pharmaceutical education in the wake of genomic technologies for drug development and personalized medicine.  Eur J Pharm Sci.  2002;15:243–50.[PubMed]
 
Frueh FW, Gurwitz D. From pharmacogenetics to personalized medicine: A vital need for educating health professionals and the community.  Pharmacogenomics.  2004;5:571–9.[PubMed]
 
Lunshof J. Teaching and practicing pharmacogenomics: A complex matter.  Pharmacogenomics.  2006;7:243–6.[PubMed]
 
Gurwitz D, Lunshof JE, Dedoussis G, et al. Pharmacogenomics education: International Society of Pharmacogenomics recommendations for medical, pharmaceutical, and health schools deans of education Pharmacogenomics J.  2005;5:221–5.[PubMed]
 
Gibbs N. The secret of life TIME Magazine. 2003;161(7):42–5.
 
Freimer N, Sabatti C. The human phenome project.  Nat Genet.  2003;34:15–21.[PubMed]
 
Guttmacher AE, Collins FS.  Genomic medicine: A primer.  N Engl J Med.  2002;347:1512–20.[PubMed]
 
Need AC, Motulsky AG, Goldstein DB.  Priorities and standards in pharmacogenetic research.  Nat Genet.  2005;37:671–81.[PubMed]
 
Lesko LJ, Woodcock J. Translation of pharmacogenomics and pharmacogenetics: A regulatory perspective.  Nat Rev Drug Discov.  2004;3:763–9.[PubMed]
 
Chiquette E, Amato MG, Bussey HI.  Comparison of an anticoagulation clinic with usual medical care: Anticoagulation control, patient outcomes, and health care costs.  Arch Intern Med.  1998;158:1641–7.[PubMed]
 
Donovan JL, Drake JA, Whittaker P, Tran MT.  Pharmacy-managed anticoagulation: Assessment of in-hospital efficacy and evaluation of financial impact and community acceptance.  J Thromb Thrombolysis.  2006;22:23–30.[PubMed]
 
Tschol N, Lai DK, Tilley JA, et al. Comparison of physician- and pharmacist-managed warfarin sodium treatment in open heart surgery patients Can J Cardiol.  2003;19:1413–7.[PubMed]
 
Bond CA, Raehl CL.  Clinical and economic outcomes of pharmacist-managed antiepileptic drug therapy.  Pharmacotherapy.  2006;26:1369–78.[PubMed]
 
Till LT, Voris JC, Horst JB.  Assessment of clinical pharmacist management of lipid-lowering therapy in a primary care setting.  J Manag Care Pharm.  2003;9:269–73.[PubMed]
 
Ellis SL, Carter BL, Malone DC, et al. Clinical and economic impact of ambulatory care clinical pharmacists in management of dyslipidemia in older adults: The IMPROVE study: Impact of Managed Pharmaceutical Care on Resource Utilization and Outcomes in Veterans Affairs Medical Centers Pharmacotherapy.  2000;20:1508–16.[PubMed]
 
Lee JK, Grace KA, Taylor AJ.  Effect of a pharmacy care program on medication adherence and persistence, blood pressure, and low-density lipoprotein cholesterol: A randomized controlled trial.  JAMA.  2006;296:2563–71.[PubMed]
 
Levine MN, Raskob G, Landefeld S, Hirsh J. Hemorrhagic complications of anticoagulant treatment.  Chest.  1995;108 (4 suppl):276S–290S.[PubMed]
 
Landefeld CS, Beyth RJ.  Anticoagulant-related bleeding: Clinical epidemiology, prediction, and prevention.  Am J Med.  1993;95:315–28.[PubMed]
 
Takahashi H, Echizen H. Pharmacogenetics of CYP2C9 and interindividual variability in anticoagulant response to warfarin.  Pharmacogenomics J.  2003;3:202–14.[PubMed]
 
Tabrizi AR, Zehnbauer BA, Borecki IB, et al. The frequency and effects of cytochrome P450 (CYP) 2C9 polymorphisms in patients receiving warfarin J Am Coll Surg.  2002;194:267–73.[PubMed]
 
Furuya H, Fernandez-Salguero P, Gregory W, et al. Genetic polymorphism of CYP2C9 and its effect on warfarin maintenance dose requirement in patients undergoing anticoagulation therapy Pharmacogenetics.  1995;5:389–92.[PubMed]
 
Higashi MK, Veenstra DL, Kondo LM, et al. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy JAMA.  2002;287:1690–8.[PubMed]
 
 FDA approves updated warfarin (Coumadin) prescribing information Accessed at www.fda.gov/bbs/topics/NEWS/2007/NEW01684.html, January 14,  2008.
 
D'Andrea G, D'Ambrosio RL, Di Perna P, et al. A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin Blood.  2005;105:645–9.[PubMed]
 
Oren E, McCart G, Phillips KA.  Evaluating the potential impact of pharmacogenomics on ADRs.  J Manag Care Pharm.  2002;8:285–90.[PubMed]
 
Garabedian-Ruffalo SM, Gray DR, Sax MJ, Ruffalo RL.  Retrospective evaluation of a pharmacist-managed warfarin anticoagulation clinic.  Am J Hosp Pharm.  1985;42:304–8.[PubMed]
 
Dager WE, Branch JM, King JH, et al. Optimization of inpatient warfarin therapy: Impact of daily consultation by a pharmacist-managed anticoagulation service Ann Pharmacother.  2000;3:567–72.
 
Sconce EA, Khan TI, Wynne HA, et al. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: Proposal for a new dosing regimen Blood.  2005;106:2329–33.[PubMed]
 
Phillips KA, Van Bebber SL.  Regulatory perspectives on pharmacogenomics: A review of the literature on key issues faced by the United States Food and Drug Administration.  Med Care Res Rev.  2006;63:301–26.[PubMed]
 
Ezzeldin HH, Diasio RB.  Genetic testing in cancer therapeutics.  Clin Cancer Res.  2006;12:4137–41.[PubMed]
 
Lee W, Lockhart AC, Kim RB, Rothenberg ML.  Cancer pharmacogenomics: Powerful tools in cancer chemotherapy and drug development.  Oncologist.  2005;10:104–11.[PubMed]
 
 Camptosar [package insert]. New York:  Pfizer;  2006.
 
Massacesi C, Terrazzino S, Marcucci F, et al. Uridine diphosphate glucuronosyl transferase 1A1 promoter polymorphism predicts the risk of gastrointestinal toxicity and fatigue induced by irinotecan-based chemotherapy Cancer.  2006;106:1007–16.[PubMed]
 
Innocenti F, Undevia SD, Iyer L, et al. Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan J Clin Oncol.  2004;22:1382–8.[PubMed]
 
Iyer L, Das S, Janisch L, et al. UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity Pharmacogenomics J.  2002;2:43–7.[PubMed]
 
Evans WE, Horner M, Chu YQ, et al. Altered mercaptopurine metabolism, toxic effects, and dosage requirement in a thiopurine methyltransferase-deficient child with acute lymphocytic leukemia J Pediatr.  1991;119:985–9.[PubMed]
 
Evans WE, Hon YY, Bomgaars L, et al. Preponderance of thiopurine S-methyltransferase deficiency and heterozygosity among patients intolerant to mercaptopurine or azathioprine J Clin Oncol.  2001;19:2293–301.[PubMed]
 
Stanulla M, Schaeffeler E, Flohr T, et al. Thiopurine methyltransferase (TPMT) genotype and early treatment response to mercaptopurine in childhood acute lymphoblastic leukemia JAMA.  2005;293:1485–9.[PubMed]
 
 Purinethol [package insert]. Greenville, N.C.:  DSM Pharmaceuticals:  2003.
 
Gardiner SJ, Begg EJ.  Pharmacogenetic testing for drug metabolizing enzymes: Is it happening in practice? Pharmacogenet Genomics.  2005;15:365–9.[PubMed]
 
Van Bebber SL, Keegan HL, Phillips KA, Issa AM.  Novel personalized medicine technology: UGT1A1 testing for irinotecan as a case study.  Future Medicine.  2006;3:415–9.
 
 Toxicity/benefit ratio optimization of chemotherapy in colorectal cancer (CRC) patients by determination of individual genotype determinants Accessed at www.clinicaltrials.gov/ct/show/NCT00138060?order=1, December 7,  2006.
 
 DHPLC determination of TPMT polymorphisms Accessed at www.clinicaltrials.gov/ct/show/NCT00402090?order=1, December 7,  2006.
 
van den Akker-Van Marle ME, Gurwitz D, Detmar SB, et al. Cost-effectiveness of pharmacogenomics in clinical practice: A case study of thiopurine methyltransferase genotyping in acute lymphoblastic leukemia in Europe Pharmacogenomics.  2006;7:783–92.[PubMed]
 
Hampton T. Researchers draft guidelines for clinical use of pharmacogenomics.  JAMA.  2006;296:1453–4.[PubMed]
 
NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).
Please read the other comments before you post yours. Comments are moderated and will appear on the site at the discertion of the editorial staff.
* = Required Field
(if multiple authors, separate names by comma)
Example: John Doe



Related Content

Customize your page view by dragging & repositioning the boxes below.

JAPhA Articles
Topic Collections
PubMed Articles
Advertisement
 
  • Print
  • PDF Download
  • Email
  • Share
  • Get Citation
  • Submit Comment
  • Article Alerts
    Please Wait... Processing your request... Please Wait.
    You must sign in to sign-up for alerts.

    Please confirm that your email address is correct, so you can successfully receive this alert.

  • Letters To Editor
  • Reprints